Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus could halve the grid's electrical losses using its nano-infused copper
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.11 per share a year ago.
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. ( ARCT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Neda Safarzadeh - Vice President and Head of IR/PR & Marketing Joseph Payne - Founder, President, CEO & Director Andrew Sassine - CFO & Director Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jake Batchelder - William Blair & Company L.L.C., Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Joohwan Kim Thomas Shrader - BTIG, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $0.26 per share a year ago.
